Dicerna pharmaceuticals tender offer
WebDicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) is a biopharmaceutical company focused on discovering, developing and commercialising medicines that are designed to leverage RNAi to ... tender offer. DICERNA’S STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO … WebApr 5, 2024 · Under the terms of the agreement, Novo Nordisk will commence a cash tender offer to acquire all outstanding shares of Dicerna common stock for USD 38.25 per share in cash for a total equity value of approximately USD 3.3 billion. “The acquisition of Dicerna accelerates Novo Nordisk’s research within RNAi and expands the usage of the …
Dicerna pharmaceuticals tender offer
Did you know?
WebThis Tender Offer Statement on Schedule TO (this “Schedule TO”) relates to the offer by NNUS New Research, Inc., a Delaware corporation (“Purchaser”), and Novo Nordisk …
WebDec 9, 2024 · Subject: Dicerna Pharmaceuticals, Inc. – Tender Offer Option Symbol: DRNA Date: 12/22/21 Dicerna Pharmaceuticals, Inc. (DRNA) is the subject of an Offer … WebDec 25, 2024 · Novo Nordisk has filed a Tender Offer Statement on Schedule TO with the SEC containing an offer to purchase all of the outstanding shares of Dicerna common …
WebNov 18, 2024 · Upon the successful completion of the tender offer, Novo Nordisk’s acquisition subsidiary will be merged into Dicerna, and any remaining shares of common … WebNov 18, 2024 · Upon the successful completion of the tender offer, Novo Nordisk’s acquisition subsidiary will merge into Dicerna, and any shares of common stock of …
WebWe go right to the source. Genes play a primary role in thousands of diseases. At Dicerna, we use our proprietary GalXC™ platform to develop RNAi therapies that aim to target …
WebUnder the terms of the agreement, Novo Nordisk, through a subsidiary, will initiate a tender offer to acquire all outstanding shares of Dicerna common stock at a price of $38.25 per … book of jasher 10WebDicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. ... Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire ... book of japanese mythologyWebThis Dicerna Pharmaceuticals, Inc. Third Amended and Restated 2007 Employee, Director and Consultant Stock Plan was duly adopted by the Board of Directors and stockholders of Dicerna Pharmaceuticals, Inc. (the “Company”) on July 8, 2008, and amends, restates and supersedes in its entirety the Dicerna Pharmaceuticals, Inc. god\\u0027s mighty menWebDec 8, 2024 · DRNA Dicerna Pharmaceuticals Inc Amended Tender Offer Statement by Third Party (sc To-t/a) ... Purchaser to purchase all of the outstanding shares of common … god\u0027s mighty menWebFollowing the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstanding shares of common stock of Dicerna at a price of USD 38.25 per share in cash, without interest and less any applicable tax withholding. ... Novo Nordisk to acquire Dicerna Pharmaceuticals including the RNAi research ... book of jasher 11WebDec 27, 2024 · -- Novo Nordisk on Thursday reached a definitive agreement to acquire Dicerna Pharmaceuticals with a cash tender offer of $38.25 per share, for a total value of around $3.3 billion. The closing of... April 11, 2024 god\u0027s mighty men- conference in wyWebDec 8, 2024 · Dicerna Pharmaceuticals, Inc. (Name of Subject Company) Dicerna Pharmaceuticals, Inc. ... 2024, relating to the tender offer by NNUS New Research, … god\u0027s mighty hand and outstretched arm